keynote-775 subgroup analysis in advanced endometrial cancer
Published 2 years ago • 656 plays • Length 3:28Download video MP4
Download video MP3
Similar videos
-
3:24
endometrial cancer health outcomes: pembrolizumab for patients with msi-high endometrial cancer
-
0:49
research priorities for metastatic endometrial cancer
-
2:51
molecular classification and adjuvant treatment in endometrial cancer
-
2:27
improved subtype characterization of endometrial cancer
-
45:54
molecular classification of endometrial cancer and targeted therapy considerations
-
0:56
exciting prospects for endometrial cancer treatment
-
1:16
keynote 826: pembrolizumab chemo in patients with advanced cervical cancer
-
1:42
future of precision medicine in endometrial cancer
-
2:56
keynote-177: final pfs analysis of pembrolizumab in patients with msi-h/dmmr mcrc
-
1:10
deep learning risk prediction model of distant recurrence from h&e endometrial cancer slides
-
1:01
dr. backes on the film trial in endometrial cancer
-
36:22
modern, molecularly informed therapy for patients with advanced endometrial cancer
-
1:22
dr. zamarin on the role of pembrolizumab in endometrial cancer
-
8:23
high reward, high toxicity: combination pembrolizumab and lenvatinib in advanced endometrial cancer
-
39:27
lg pathlab webinars - molecular classification of endometrial carcinoma & its role in management
-
5:16
long term results show major advance in endometrial cancer
-
0:54
current and future areas of interest in the research of endometrial cancer
-
0:57
dr. makker on combination approaches in endometrial cancer
-
4:02
#esmo19: lenvatinib (len) and pembrolizumab (pembro) in advanced endometrial cancer